Importance of the leukotriene B4-BLT1 and LTB4-BLT2 pathways in asthma

EW Gelfand - Seminars in immunology, 2017 - Elsevier
EW Gelfand
Seminars in immunology, 2017Elsevier
For several decades, the leukotriene pathways have been implicated as playing a central
role in the pathophysiology of asthma. The presence and elevation of numerous metabolites
in the blood, sputum, and bronchoalveolar lavage fluid from asthmatics or experimental
animals adds support to this notion. However, targeting of the leukotriene pathways has had,
in general, limited success. The single exception in asthma therapy has been targeting of
the cysteinyl leukotriene receptor 1, which clinically has proven effective but only in certain …
Abstract
For several decades, the leukotriene pathways have been implicated as playing a central role in the pathophysiology of asthma. The presence and elevation of numerous metabolites in the blood, sputum, and bronchoalveolar lavage fluid from asthmatics or experimental animals adds support to this notion. However, targeting of the leukotriene pathways has had, in general, limited success. The single exception in asthma therapy has been targeting of the cysteinyl leukotriene receptor 1, which clinically has proven effective but only in certain clinical situations. Interference with 5-lipoxygenase has had limited success, in part due to adverse drug effects. The importance of the LTB4-BLT1 pathway in asthma pathogenesis has extensive experimental support and findings, albeit limited, from clinical samples. The LTB4-BLT1 pathway was shown to be important as a neutrophil chemoattractant. Despite observations made more than two decades ago, the LTB4-BLT1 pathway has only recently been shown to exhibit important activities on subsets of T lymphocytes, both as a chemoattractant and on lymphocyte activation, as well as on dendritic cells, the major antigen presenting cell in the lung. The role of BLT2 in asthma remains unclear. Targeting of components of the LTB4-BLT1 pathway offers innovative therapeutic opportunities especially in patients with asthma that remain uncontrolled despite intensive corticosteroid treatment.
Elsevier